Abstract
A promotional communications strategy is considered early in prescription medical product development by commercial disciplines (e.g., commercial/marketing) and informs promotional materials to key stakeholders such as healthcare providers and patients. Health economics and outcomes research (HEOR) is a scientific discipline that is also responsible for the generation of promotional materials to other key stakeholders such as payors. The overarching promotional strategy benefits from consistent partnerships with regulatory affairs colleagues, culminating in cost savings and patient-centric promotional materials. Yet there is a paucity of published content that details effective collaboration between promotional teams and regulatory colleagues prior to medical/legal/regulatory (MLR) review. The following review aims to showcase such organizational innovation from the perspective of teams develo** promotional materials (i.e., commercial and HEOR). Behind-the-scenes marketing activities are described in relation to the following key steps that build the strategy’s foundation: insight gathering from key stakeholders; sub-strategy development; tactic identification; and promotional message development. Integration of regulatory colleagues with teams develo** promotional materials is imperative to accomplish these key steps prior to any MLR review. Finally, four themes in best practices for collaboration with regulatory colleagues are shared from the perspective of commercial disciplines and HEOR, alongside a real-world example for each: (1) Alignment of Strategies; (2) Shared Process & Tools; (3) Creative Problem-Solving; and (4) Culture of Connecting.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs43441-021-00272-1/MediaObjects/43441_2021_272_Fig1_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs43441-021-00272-1/MediaObjects/43441_2021_272_Fig2_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs43441-021-00272-1/MediaObjects/43441_2021_272_Fig3_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs43441-021-00272-1/MediaObjects/43441_2021_272_Fig4_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs43441-021-00272-1/MediaObjects/43441_2021_272_Fig5_HTML.png)
Similar content being viewed by others
References
Wouters O, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. J Am Med Assoc. 2020;323(9):844–53. https://doi.org/10.1001/jama.2020.1166.
Schwartz LM, Woloshin S. Medical marketing in the United States, 1997–2016. J Am Med Assoc. 2019;321(1):80–96. https://doi.org/10.1001/jama.2018.19320.
FDA. Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities – Questions and Answers: Final Guidance for Industry and Review Staff. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-and-device-manufacturer-communications-payors-formulary-committees-and-similar-entities.
Cook PB, Purcell T, Subramanyam J, Golan E, Phinney T, Totosy de Zepetnek J. Regulatory Insights Throughout the Commercialization Realm and Product Lifecycle. Virtual Conference: RAPS Convergence; 2020.
Mantus DS. The practice of regulatory affairs. In: Mantus D, Pisano DJ, editors. FDA regulatory affairs. 3rd ed. New York: Taylor and Francis Group, LLC; 2014. p. 309–26.
Karstrom K. Collaboration to win with regulatory teams. Motionstrand Website. https://www.motionstrand.com/news/collaborating-win-regulatory-teams.
Robinson R. Collaboration within the commercialization process. PharmaVOICE. https://www.pharmavoice.com/article/2017-4-commercialization/.
Geissler J, Ryll B, di Priolo SL, Uhlenhopp M. Improving patient involvement in medicines research and development: a practical roadmap. Ther Innov Regul Sci. 2017;51(5):612–9. https://doi.org/10.1177/2168479017706405.
Mezher M. Researchers link target product profiles to shorter review times. Regulatory Affairs Professional Society (RAPS). https://www.raps.org/regulatory-focus™/news-articles/2017/4/researchers-link-target-product-profiles-to-shorter-review-times.
Dillon C, Knapp J, Stinson M. An evolved approach to advisory boards in rare disease drug development: 5-step model to finding and engaging patient advisors. J Patient Exp. 2020;7(6):978–81. https://doi.org/10.1177/2374373520948441.
Aikin KJ, Sullivan HW, Betts KR. Disease information in direct-to-consumer prescription drug print ads. J Health Commun. 2016;21(2):228–39. https://doi.org/10.1080/10810730.2015.1058440.
Raber-Johnson ML, Gallwitz WE, Sullivan EJ, Storer P. Innovation in clinical trial design and product promotion: evolving the patient perspective with regulatory and technological advances. Ther Innov Regul Sci. 2020;54(3):519–27. https://doi.org/10.1007/s43441-019-00083-5.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Raber-Johnson, M.L., Stinson, M., Dillon, C. et al. Key Steps Toward a Promotional Communications Strategy: Collaboration Best Practices for Teams Creating Promotional Materials and Regulatory Colleagues. Ther Innov Regul Sci 55, 696–704 (2021). https://doi.org/10.1007/s43441-021-00272-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s43441-021-00272-1